Drug Interactions between fenfluramine and Lonsurf
This report displays the potential drug interactions for the following 2 drugs:
- fenfluramine
- Lonsurf (tipiracil/trifluridine)
Interactions between your drugs
fenfluramine tipiracil
Applies to: fenfluramine and Lonsurf (tipiracil / trifluridine)
MONITOR: Coadministration with fenfluramine may increase the plasma concentrations of drugs that are substrates of the multidrug and toxin extrusion 1 (MATE-1) efflux transporter. Fenfluramine is an inhibitor of the MATE-1 efflux transporter in vitro. However, clinical data are not available.
MANAGEMENT: Until more information is available, caution is advised when fenfluramine is coadministered with drugs that are substrates of the multidrug and toxin extrusion 1 (MATE-1) efflux transporter, particularly those with a narrow therapeutic range. If coadministration is required, clinical and laboratory monitoring for drug-related toxicities should be considered and the dosage adjusted as necessary in accordance with the product labeling of the coadministered drug.
References (3)
- (2023) "Product Information. Fintepla (fenfluramine)." UCB Pharma Ltd, SUPPL-13
- (2024) "Product Information. Fintepla (fenfluramine)." UCB Australia Pty Ltd T/A UCB Pharma Division of UCB Australia
- (2023) "Product Information. Fintepla (fenfluramine)." Prescript Pharmaceuticals, SUPPL-13
Drug and food interactions
fenfluramine food
Applies to: fenfluramine
GENERALLY AVOID: Alcohol may potentiate the central nervous system and cardiovascular effects of centrally-acting appetite suppressants. In one study, concurrent administration of methamphetamine (30 mg intravenously) and ethanol (1 gm/kg orally over 30 minutes) increased heart rate by 24 beats/minute compared to methamphetamine alone. This increases cardiac work and myocardial oxygen consumption, which may lead to more adverse cardiovascular effects than either agent alone. Subjective effects of ethanol were diminished in the eight study subjects, but those of methamphetamine were not affected. The pharmacokinetics of methamphetamine were also unaffected except for a decrease in the apparent volume of distribution at steady state.
MANAGEMENT: Concomitant use of centrally-acting appetite suppressants and alcohol should be avoided if possible, especially in patients with a history of cardiovascular disease. Patients should be counselled to avoid hazardous activities requiring complete mental alertness and motor coordination until they know how these agents affect them, and to notify their physician if they experience excessive or prolonged CNS effects that interfere with their normal activities.
References (3)
- Mendelson J, Jones RT, Upton R, Jacob P 3rd (1995) "Methamphetamine and ethanol interactions in humans." Clin Pharmacol Ther, 57, p. 559-68
- (2001) "Product Information. Didrex (benzphetamine)." Pharmacia and Upjohn
- (2012) "Product Information. Suprenza (phentermine)." Akrimax Pharmaceuticals
trifluridine food
Applies to: Lonsurf (tipiracil / trifluridine)
ADJUST DOSING INTERVAL: Administration of trifluridine-tipiracil with a standardized high-fat, high-calorie meal has been shown to decrease trifluridine peak plasma concentration (Cmax) as well as tipiracil Cmax and systemic exposure (AUC) by approximately 40% compared to administration in a fasting state in patients with cancer given a single 35 mg/m2 dose. No change in trifluridine AUC was observed.
MANAGEMENT: Based on the observed correlation between increases in the Cmax of trifluridine and decreases in neutrophil counts, trifluridine-tipiracil should be taken within one hour after completion of the morning and evening meals.
References (1)
- (2015) "Product Information. Lonsurf (tipiracil-trifluridine)." Taiho Oncology, Inc.
Therapeutic duplication warnings
No warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
See also
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.